Johnson & Johnson

J&J, Momenta Pharma file patent infringement lawsuit against Natco, Mylan

Johnson & Johnson and Momenta Pharmaceuticals lawsuit alleges infringement of two old patents associated with 20mg/ml and 40mg/ml Glatiramer Acetate injection, Natco said in a regulatory filing.

Updated On : 02 Aug 2023 | 10:18 AM IST

Johnson & Johnson suspends its Covid-19 vaccine sales forecasts

Johnson & Johnson is suspending sales forecasts for its COVID-19 vaccine only a few months after saying the shot could bring in as much as USD 3.5 billion this year. The health care giant said Tuesday that a global supply surplus and demand uncertainty prompted the move, which will not affect the company's operational earnings per share guidance. J&J's one-shot vaccine brought in USD 457 million in global sales during the first quarter, with most of that coming from outside the United States. The vaccine brought in only USD 75 million in sales in the US, or about 25 per cent less than what it rang up after debuting in last year's first quarter. J&J has said it doesn't intend to profit from the vaccine. But it said in January that it could bring in between USD 3 billion and USD 3.5 billion in sales this year, as countries continue to fight variants of the virus. The vaccine brought in USD 2.38 billion in sales last year. Vaccine options from rival drugmakers Pfizer and ...

Updated On : 19 Apr 2022 | 6:44 PM IST

Johnson & Johnson to stop selling personal care products in Russia

(Reuters) -Johnson & Johnson said on Tuesday it would halt sale of personal care products in Russia, joining other companies that have limited their business in the country in response to its invasion of Ukraine.

Updated On : 29 Mar 2022 | 8:08 PM IST

J&J expects Covid vaccine sales to jump as much as 46% in 2022

Delivery delays and an uneven demand during last year resulted in the drugmaker narrowly missing its goal of garnering $2.50 billion in vaccine sales in 2021.

Updated On : 25 Jan 2022 | 6:19 PM IST

CDC panel recommends Pfizer, Moderna Covid vaccine shots over J&J's

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday. The strange clotting problem has caused nine confirmed deaths after J&J vaccinations while the Pfizer and Moderna vaccines don't come with that risk and also appear more effective, advisers to the Centers for Disease Control and Prevention said. It's an unusual move and the CDC's director, Dr. Rochelle Walensky, must decide whether to accept the panel's advice. Until now the U.S. has treated all three COVID-19 vaccines available to Americans as an equal choice, since large studies found they all offered strong protection and early supplies were limited. J&J's vaccine initially was welcomed as a single-dose option that could be especially important for hard-to-reach groups like homeless people who might not get the needed second dose of the Pfizer or Moderna options. But the CDC's ...

Updated On : 17 Dec 2021 | 6:50 AM IST

CDC panel recommends Pfizer, Moderna Covid vaccines over J&J shot

Most Americans should be given the Pfizer or Moderna vaccines instead of the Johnson & Johnson shot that can cause rare but serious blood clots, U.S. health advisers recommended Thursday. The strange clotting problem has caused nine confirmed deaths after J&J vaccinations while the Pfizer and Moderna vaccines don't come with that risk and also appear to be more effective, advisers to the Centers for Disease Control and Prevention said. It's an unusual move and the CDC's director, Dr. Rochelle Walensky, must decide whether to accept the panel's advice. Until now the U.S. has treated all three COVID-19 vaccines available to Americans as an equal choice, since large studies found they all offered strong protection and early supplies were limited. J&J's vaccine initially was welcomed as a single-dose option that could be especially important for hard-to-reach groups like homeless people who might not get the needed second dose of the Pfizer or Moderna options. But the CDC's ..

Updated On : 17 Dec 2021 | 3:08 AM IST

US CDC to discuss limiting J&J vaccine due to rare blood clot issue: Report

Vaccine advisers with the US CDC will meet on Thursday to discuss potentially limiting the use of the Johnson and Johnson vaccine due to persistent blood clot issues

Updated On : 16 Dec 2021 | 10:53 AM IST

Johnson & Johnson plans to split into drug and consumer companies

The health-care giant will split off its consumer division in 18 to 24 months, the company said in a statement

Updated On : 13 Nov 2021 | 1:20 AM IST

Johnson & Johnson plans to split into two companies

Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.

Updated On : 12 Nov 2021 | 8:56 PM IST

US cancels Covid-19 vaccine maker's multimillion dollar deal: Report

The federal government has canceled a multimillion dollar deal with Emergent BioSolutions, a Maryland-based vaccine manufacturer with facilities in Baltimore that were found to have produced millions of contaminated Johnson & Johnson vaccine doses this spring, the Washington Post reported. Emergent disclosed the development Thursday in a conference call discussing its latest financial results, the Post reported. Emergent said it will forgo about USD 180 million due to the contract's termination, according to the Post. Emergent BioSolutions played a role in the Trump administration's effort to speed up vaccine development and distribution. But after winning a contract from the previous administration, Emergent quickly ran into production problems. In March, ingredients intended for use in producing the Oxford-AstraZeneca vaccine shots contaminated 15 million doses of the Johnson & Johnson vaccine. The problems with the vaccines caused a monthslong delay in production. After ...

Updated On : 05 Nov 2021 | 3:09 PM IST

US FDA clears Moderna, J&J booster shots; backs Covid-19 vaccine mixing

Pfizer and BioNTech said a booster shot of their Covid-19 vaccine restored full protection in a large study, results that are likely to bolster the argument for giving a third dose more widely

Updated On : 21 Oct 2021 | 10:21 PM IST

FDA panel takes up tough questions on J&J Covid-19 boosters

U.S. health advisers on Friday tackled who should get boosters of Johnson & Johnson's single-shot COVID-19 vaccine and when - and whether using a competing brand for the second dose might provide better protection. The push for boosters kicked off last month after the Food and Drug Administration authorized third doses of the Pfizer vaccine for seniors and younger adults with health problems, jobs or living conditions that place them at higher risk from the coronavirus. On Thursday, an FDA advisory panel unanimously recommended a half-dose booster of the similar Moderna vaccine for the same groups. Friday, the same panel discussed a booster of J&J's vaccine but the decision is more complex. Moderna and Pfizer asked the FDA to OK boosters at least six months after immunization, but J&J proposed a sliding schedule with an extra dose as early as two months later. Adding another twist, the experts also will discuss preliminary data from a government mix-and-match study that ...

Updated On : 16 Oct 2021 | 12:41 AM IST